Michelle Dawson posts

Post published on Bluesky on 18 Dec 2024 10:53

Back to posts Previous post Next post
Bluesky Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms
Open original post
View on Bluesky

Information about the link integrated into the post

Clinical trial

Centre for Addiction and Mental Health (2024). Psilocybin for Treatment-Resistant Depression in Autism. ClinicalTrials.gov. Centre for Addiction and Mental Health.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Centre for Addiction and Mental Health (2024). Psilocybin for Treatment-Resistant Depression in Autism. ClinicalTrials.gov. Centre for Addiction and Mental Health.

Publication date
1 Nov 2024
Identifier
NCT06731621
Authors
Centre for Addiction and Mental Health
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Centre for Addiction and Mental Health
Metadata source
clinicaltrials.gov

Abstract

We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020). They will also receive psilocybin at 2 different time points, firstly a safety dose of 10mg, followed by a treatment dose of 25mg. This study design is in accordance with previous studies investigating the use of psilocybin with psilocybin-assisted therapy (PAT) to treat TRD (Carhart-Harris et al., 2016, 2018)

Open source